2020 ttf alk session qa panel reducing dosage on lorlatinib vs switching to a different agent
Published 3 years ago • 19 plays • Length 1:43Download video MP4
Download video MP3
Similar videos
-
2:34
2020 ttf alk session qa panel next steps after progression on lorlatinib
-
3:06
2020 ttf alk session qa panel progression on 2nd-gen alk inhibitor if biopsy shows no alk mutation
-
4:20
video 2020 ttf alk/ros session qa panel the efficacy of dose reduction or interruption of crizotinib
-
1:50
2020 ttf alk/ros session qa panel the difference in efficacy of tkis in different patients
-
2:16
2020 ttf alk session qa panel ros1 patients on immunotherapy chemotherapy combinations
-
2:36:50
grace assembly klang // mandarin service // 10th august 2024, 7.45pm.
-
2:37
crown: lorlatinib in treatment-naïve patients with alk-positive advanced nsclc
-
1:21:42
dr. lin and dr gainor with colin barton
-
2:16
2020 ttf alk session qa panel using ctc profiling to detect crizotinib resistance on progression
-
2:36
2020 ttf alk session qa panel information on the crown trial and firstline lorlatinib
-
4:08
2020 ttf alk/ros session qa panel treatment decisions for simultaneous egfr and ros1 mutation
-
23:44
2020 ttf alk session raez sequence of alk inhibitors
-
3:46
2020 ttf alk session qa panel the use of an alk tki post chemoradiation for stage 3b lung cancer
-
3:12
q&a: new lesions - switch from alectinib to lorlatinib? targeted therapies in lung cancer 2023
-
3:24
2020 ttf alk qa panel ros1 clinical trial updates
-
1:39
2020 ttf egfr session qa panel what is the difference between c797s and c797x
-
25:07
2020 ttf alk session - lin - tkis for ros1
-
1:57
video 2020 ttf alk/ros session qa panel ros1 patients - chemo after resistance to inhibitor therapy?
-
2:39
grace targeted therapies lung cancer 2021 - return to alectinib -progression on lorlatinib in alk
-
1:20
2020 ttf alk/ros session qa panel ros1 patient on crizotinib, brain metastases treated with srt
-
7:09
2020 ttf egfr session - qa panel preferred chemo regimen when targeted therapy options are exhausted